Safety of Dual‐Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease

BACKGROUND: Although recommended in the guidelines, the safety of chronic P2Y(12) inhibitor therapy in patients with chronic kidney disease (CKD) after an acute myocardial infarction (MI) is not well studied. METHODS AND RESULTS: The TRANSLATE‐ACS (Treatment with ADP Inhibitors: Longitudinal Assessm...

Descripción completa

Detalles Bibliográficos
Autores principales: Rymer, Jennifer A., Kaltenbach, Lisa A., Doll, Jacob A., Messenger, John C., Peterson, Eric D., Wang, Tracy Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585341/
https://www.ncbi.nlm.nih.gov/pubmed/31070112
http://dx.doi.org/10.1161/JAHA.119.012236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585341/
https://www.ncbi.nlm.nih.gov/pubmed/31070112
http://dx.doi.org/10.1161/JAHA.119.012236

Ejemplares similares